{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:35:25Z","timestamp":1792647325961,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T00:00:00Z","timestamp":1506384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T00:00:00Z","timestamp":1506384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/bjc.2017.327","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T20:02:15Z","timestamp":1506456135000},"page":"153-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours"],"prefix":"10.1038","volume":"118","author":[{"given":"Jeffrey R","family":"Infante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S","family":"Dychter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Maneval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Michael","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh K","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,26]]},"reference":[{"key":"BFbjc2017327_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/sj.ijir.3901232","volume":"16","author":"D Abbott","year":"2004","unstructured":"Abbott D, Comby P, Charuel C, Graepel P, Hanton G, Leblanc B, Lodola A, Longeart, Paulus L, Peters G, Stadler J (2004) Preclinical safety profile of sildenafil. Int J Impot Res 16: 498\u2013504.","journal-title":"Int J Impot Res"},{"issue":"9","key":"BFbjc2017327_CR2","first-page":"1607","volume":"2","author":"V Abetamann","year":"1996","unstructured":"Abetamann V, Kern HF, Elsasser HP (1996) Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res 2 (9): 1607\u20131618.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"BFbjc2017327_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1634\/theoncologist.2008-0119","volume":"14","author":"M Allen-Auerbach","year":"2009","unstructured":"Allen-Auerbach M, Weber WA (2009) Measuring response with FDG-PET: methodological aspects. Oncologist 14 (4): 369\u2013377.","journal-title":"Oncologist"},{"issue":"2","key":"BFbjc2017327_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0002-9440(10)64757-8","volume":"156","author":"P Auvinen","year":"2000","unstructured":"Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM (2000) Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156 (2): 529\u2013536.","journal-title":"Am J Pathol"},{"issue":"1","key":"BFbjc2017327_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0304-3835(98)00204-3","volume":"131","author":"G Baumgartner","year":"1998","unstructured":"Baumgartner G, Gomar-Hoss C, Sakr L, Ulsperger E, Wogritsch C (1998) The impact of extracellular matrix on the chemoresistance of solid tumors\u2014experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 131 (1): 85\u201399.","journal-title":"Cancer Lett"},{"issue":"1","key":"BFbjc2017327_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.2910520102","volume":"52","author":"P Bertrand","year":"1992","unstructured":"Bertrand P, Girard N, Delpech B, Duval C, d\u2019Anjou J, Dauce JP (1992) Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas. Int J Cancer 52 (1): 1\u20136.","journal-title":"Int J Cancer"},{"key":"BFbjc2017327_CR7","doi-asserted-by":"publisher","first-page":"36928","DOI":"10.1038\/srep36928","volume":"6","author":"Y Dong","year":"2016","unstructured":"Dong Y, Arif A, Olsson M, Cali V, Hardman B, Dosanjh M, Lauer M, Midura RJ, Hascall VC, Brown KL, Johnson P (2016) Endotoxin free hyaluronan and hyaluronan fragments do not stimulate TNF-\u03b1, interleukin-12 or upregulate co-stimulatory molecules in dendritic cells or macrophages. Sci Rep 6: 36928.","journal-title":"Sci Rep"},{"issue":"1","key":"BFbjc2017327_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1365-2796.1997.00170.x","volume":"242","author":"JR Fraser","year":"1997","unstructured":"Fraser JR, Laurent TC, Laurent UB (1997) Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 242 (1): 27\u201333.","journal-title":"J Intern Med"},{"issue":"2","key":"BFbjc2017327_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1006\/abio.1997.2262","volume":"251","author":"GI Frost","year":"1997","unstructured":"Frost GI, Stern R (1997) A microtiter-based assay for hyaluronidase activity not requiring specialized reagents. Anal Biochem 251 (2): 263\u2013269.","journal-title":"Anal Biochem"},{"issue":"1 Pt 2","key":"BFbjc2017327_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/019262338901700109","volume":"17","author":"TJ Hayes","year":"1989","unstructured":"Hayes TJ, Roberts GK, Halliwell WH (1989) An idiopathic febrile necrotizing arteritis syndrome in the dog: beagle pain syndrome. Toxicol Pathol 17 (1 Pt 2): 129\u2013137.","journal-title":"Toxicol Pathol"},{"issue":"12","key":"BFbjc2017327_CR11","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-15-2010","volume":"22","author":"SR Hingorani","year":"2016","unstructured":"Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard HM, Devoe CE (2016) Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res 22 (12): 2848\u20132854.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"BFbjc2017327_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA (2013) Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62 (1): 112\u2013120.","journal-title":"Gut"},{"issue":"4","key":"BFbjc2017327_CR13","first-page":"1203","volume":"32","author":"P Jiang","year":"2012","unstructured":"Jiang P, Li X, Thompson CB, Huang Z, Araiza F, Osgood R, Wei G, Feldmann M, Frost GI, Shepard HM (2012) Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res 32 (4): 1203\u20131212.","journal-title":"Anticancer Res"},{"issue":"4","key":"BFbjc2017327_CR14","first-page":"735","volume":"17","author":"CB Knudson","year":"1998","unstructured":"Knudson CB, Toole BP (1998) Epithelial-mesenchymal interaction in the regulation of hyaluronate production during limb development. Biochem Int 17 (4): 735\u2013745.","journal-title":"Biochem Int"},{"issue":"2014","key":"BFbjc2017327_CR15","first-page":"817613","volume":"2014","author":"A Kultti","year":"2014","unstructured":"Kultti A, Zhao C, Singha NC, Zimmerman S, Osgood RJ, Symons R, Jiang P, Li X, Thompson CB, Infante JR, Jacobetz MA, Tuveson DA, Frost GI, Shepard HM, Huang Z (2014) Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. Biomed Res Int 2014 (2014): 817613.","journal-title":"Biomed Res Int"},{"issue":"12","key":"BFbjc2017327_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","volume":"18","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Eckert L, Wang Y, Wang H, Cohen A (2013) Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist 18 (12): 1321\u20131329.","journal-title":"Oncologist"},{"issue":"9","key":"BFbjc2017327_CR17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","volume":"48","author":"A Maraveyas","year":"2012","unstructured":"Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48 (9): 1283\u20131292.","journal-title":"Eur J Cancer"},{"issue":"10","key":"BFbjc2017327_CR18","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1172\/JCI119054","volume":"98","author":"CM McKee","year":"1996","unstructured":"McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, Bao C, Noble PW (1996) Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 98 (10): 2403\u20132413.","journal-title":"J Clin Invest"},{"issue":"5-6","key":"BFbjc2017327_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/10428199409049691","volume":"14","author":"LM Pilarski","year":"1994","unstructured":"Pilarski LM, Masellis-Smith A, Belch AR, Yang B, Savani RC, Turley EA (1994) RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy? Leuk Lymphoma 14 (5-6): 363\u2013374.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"BFbjc2017327_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0304-3835(98)00205-5","volume":"131","author":"K Pillwein","year":"1998","unstructured":"Pillwein K, Fuiko R, Slavc I, Czech T, Hawliczek G, Bernhardt G, Nirnberger G, K\u00f6ller U (1998) Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Cancer Lett 131 (1): 101\u2013108.","journal-title":"Cancer Lett"},{"key":"BFbjc2017327_CR21","unstructured":"Printz MA, Babson B, Selvam P, Beyerlein D, Jiang P, Maneval DC, Sugarman BJ (2017) A Quantitative Method for Determining Hyaluronan Content in Plasma by LC\/MS\/MS and Plasma HA as a Pharmacodynamic Marker for PEGylated-Hyaluronidase PH20 (PEGPH20) in a Phase 1b Trial for Pancreatic Ductal Adenocarcinoma [poster]. Exhibited at the American Association of Pharmaceutical Sciences National Biotechnology Conference, 1-3 May 2017; San Diego, CA, USA."},{"issue":"3","key":"BFbjc2017327_CR22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21 (3): 418\u2013429.","journal-title":"Cancer Cell"},{"issue":"2","key":"BFbjc2017327_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00418-011-0896-x","volume":"137","author":"K Rilla","year":"2012","unstructured":"Rilla K, Pasonen-Seppanen S, Karna R, Karjalainen HM, Torronen K, Koistinen V, Tammi MI, Tammi RH, Ter\u00e4v\u00e4inen T, Manninen A (2012) HAS3-induced accumulation of hyaluronan in 3D MDCK cultures results in mitotic spindle misorientation and disturbed organization of epithelium. Histochem Cell Biol 137 (2): 153\u2013164.","journal-title":"Histochem Cell Biol"},{"issue":"2","key":"BFbjc2017327_CR24","first-page":"342","volume":"58","author":"K Ropponen","year":"1998","unstructured":"Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, Agren U, Alhava E, Kosma VM (1998) Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58 (2): 342\u2013347.","journal-title":"Cancer Res"},{"issue":"7-8","key":"BFbjc2017327_CR25","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.bjc.6690180","volume":"79","author":"LP Setala","year":"1999","unstructured":"Setala LP, Tammi MI, Tammi RH, Eskelinen MJ, Lipponen PK, Agren UM, Parkkinen J, Alhava EM, Kosma VM (1999) Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer 79 (7-8): 1133\u20131138.","journal-title":"Br J Cancer"},{"key":"BFbjc2017327_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fonc.2015.00192","volume":"5","author":"HM Shepard","year":"2015","unstructured":"Shepard HM (2015) Breaching the castle walls: hyaluronan depletion as a therapeutic approach to cancer therapy. Front Oncol 5: 192.","journal-title":"Front Oncol"},{"key":"#cr-split#-BFbjc2017327_CR27.1","unstructured":"Shepard HM, Frost GI, Rybak ME, Ramanathan RK, Von Hoff DD, Infante JR, Rosen S, Leff J (2010) Targeting Hyaluronan (HA) in the Tumor Stroma: Translational Evaluation of Pegylated Hyaluronidase (PEGPH20) in Animal Models and Patients with Advanced Solid Tumors [poster]. Exhibited at the 4th ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer"},{"key":"#cr-split#-BFbjc2017327_CR27.2","unstructured":"Shepard HM, Frost GI, Rybak ME, Ramanathan RK, Von Hoff DD, Infante JR, Rosen S, Leff J (2010) Targeting Hyaluronan"},{"key":"#cr-split#-BFbjc2017327_CR27.3","unstructured":"(HA) in the Tumor Stroma: Translational Evaluation of Pegylated Hyaluronidase (PEGPH20) in Animal Models and Patients with Advanced Solid Tumors [poster]. Exhibited at the 4th ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer; 18-20 October 2010; Hollywood, FL, USA."},{"issue":"3","key":"BFbjc2017327_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3): 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"BFbjc2017327_CR29","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-10-0470","volume":"9","author":"CB Thompson","year":"2010","unstructured":"Thompson CB, Shepard HM, O\u2019Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, Nadjsombati S, Frost GI (2010) Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 9 (11): 3052\u20133064.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"BFbjc2017327_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.semcancer.2008.03.009","volume":"18","author":"BP Toole","year":"2008","unstructured":"Toole BP, Slomiany MG (2008) Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 18 (4): 244\u2013250.","journal-title":"Semin Cancer Biol"},{"key":"BFbjc2017327_CR31","unstructured":"US Department of Health and Human Services (2009) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. US Department of Health and Human Services: Washington, DC, USA; NIH Publication No. 09-5410."},{"key":"BFbjc2017327_CR32","unstructured":"Veneziale RW, Printz MA, Sugarman BJ, Lalayeva N, Ruppert GW, Polhamus K, Maneval DC, Lapinskas PJ (2015) Toxicity and Toxicokinetics of PEGPH20 in the Monkey and Rat [poster]. Exhibited at the 54th annual meeting of the Society for Toxicology; 13\u201317 March 2015; New Orleans, LA, USA."},{"issue":"15","key":"BFbjc2017327_CR33","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, Hostetter G, Shepard HM, Von Hoff DD, Han H (2015) Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res 21 (15): 3561\u20133568.","journal-title":"Clin Cancer Res"},{"issue":"46","key":"BFbjc2017327_CR34","doi-asserted-by":"publisher","first-page":"45801","DOI":"10.1074\/jbc.M308168200","volume":"278","author":"A Zoltan-Jones","year":"2003","unstructured":"Zoltan-Jones A, Huang L, Ghatak S, Toole BP (2003) Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem 278 (46): 45801\u201345810.","journal-title":"J Biol Chem"}],"updated-by":[{"DOI":"10.1038\/bjc.2017.438","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2017327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017327","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:39:35Z","timestamp":1684417175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2017327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,26]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFbjc2017327"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.327","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/bjc.2017.438","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,26]]},"assertion":[{"value":"11 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2018","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JRI reports that his institution has received research funding from Halozyme Therapeutics, Inc. RLK reports being a shareholder of Imaging Endpoints Core Lab. DDVH reports receiving a research grant to his institution from Halozyme Therapeutics, Inc. and is a consultant for Imaging Endpoints. LSR reports receiving a research grant to his institution from Halozyme Therapeutics, Inc. for the conduct of these clinical trials. PLR is currently on the DSMC for the pivotal phase 3 clinical trial of PEGPH20 in pancreatic cancer, sponsored by Halozyme Therapeutics, Inc., SSD is a shareholder of stock at Halozyme Therapeutics, Inc. and full-time employee at Fate Therapeutics. SSD, JZ, and GF were employees of Halozyme Therapeutics, Inc. at the time this trial was conducted. GF is a shareholder of stock at Halozyme Therapeutics, Inc. DCM, PJ, and HMS were employees of Halozyme Therapeutics, Inc. at the time this manuscript was submitted. RKR reports receiving research funding from Merrimack Pharmaceuticals. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}